M. Valladares

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús et al. · British Journal of Cancer · 2010 · 88 citations · Full text

Tyms Genetic Variants, Oncology, Oncogenic Agent +8

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Josep Tabernero, Enrique Aranda, Alba Liliana Gil Gómez et al. · Journal of Clinical Oncology · 2010 · 39 citations

Surgical Oncology, Pathology, Maintenance Xelox-bev +17

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Enrique Aranda, Jorge Aparicio, Vicente Alonso et al. · Clinical & Translational Oncology · 2015 · 34 citations · Full text

Tumor Biology, Advanced Crc, Surgical Oncology +14

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Cristina Santos, Daniel Azuara, J.M. Viéitez et al. · Annals of Oncology · 2019 · 28 citations · Full text

Medicine, High-sensitivity Genotyping, Ultra Trial +7

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, M. Martínez-Villacampa et al. · Annals of Oncology · 2008 · 27 citations

Oncology, Digestive Tumors Study, Gastrointestinal Oncology +10